Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(5):571–581. doi: 10.1038/bjc.1997.428

Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.

F Kanzawa 1, K Nishio 1, T Ishida 1, M Fukuda 1, H Kurokawa 1, H Fukumoto 1, Y Nomoto 1, K Fukuoka 1, K Bojanowski 1, N Saijo 1
PMCID: PMC2228004  PMID: 9303354

Abstract

Drug resistance is one of the problems severely limiting chemotherapy in cancer patients. Thus, it is very important to develop new drugs that are effective against drug-resistant tumour cells. The novel anti-tumour agent NK109 has been developed from benzo[c]phenanthridine derivatives by Nippon Kayaku (Tokyo, Japan). We have confirmed that NK109 shows anti-tumour effects against a number of human tumour cell lines by inhibiting DNA topoisomerase II activity through the stabilization of the cleavable complex. Further, its efficacy against several drug-resistant tumour cell lines was also shown. NK109 showed potent anti-tumour activity against doxorubicin-resistant human tumour cell lines that have a typical multidrug resistance phenotype caused by P-glycoprotein. NK109 was not pumped extracellularly by P-glycoprotein and, consequently, NK109 accumulated in resistant cells. Cisplatin-resistant human tumour cell lines, which demonstrated decreased cisplatin accumulation, were sensitive to NK109. NK109 non-cross-resistance was confirmed using xenografts of tumour cells that were resistant to cisplatin in SCID mice. Furthermore, etoposide-resistant cells, with decreased topoisomerase II activity, were markedly sensitive to NK109 when compared with their parent cells, suggesting the possibility that the cytotoxic mechanism of NK109 differs from that of etoposide. In conclusion, NK109 is a very promising new anti-tumour drug for clinical use, because the efficacy of NK109 is not susceptible to several known molecular alterations that are associated with drug resistance. A clinical study of this compound is now in progress in Japan.

Full text

PDF
571

Images in this article

573Figure 2
on p.573
573Figure 3
on p.573
578Figure 7
on p.578
579Figure 8
on p.579

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama S., Cornwell M. M., Kuwano M., Pastan I., Gottesman M. M. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol Pharmacol. 1988 Feb;33(2):144–147. [PubMed] [Google Scholar]
  2. Bruggemann E. P., Germann U. A., Gottesman M. M., Pastan I. Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine. J Biol Chem. 1989 Sep 15;264(26):15483–15488. [PubMed] [Google Scholar]
  3. Cowan K. H., Batist G., Tulpule A., Sinha B. K., Myers C. E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9328–9332. doi: 10.1073/pnas.83.24.9328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta. 1973 Oct 25;323(3):466–483. doi: 10.1016/0005-2736(73)90191-0. [DOI] [PubMed] [Google Scholar]
  5. Deffie A. M., Batra J. K., Goldenberg G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res. 1989 Jan 1;49(1):58–62. [PubMed] [Google Scholar]
  6. Fojo A., Akiyama S., Gottesman M. M., Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 1985 Jul;45(7):3002–3007. [PubMed] [Google Scholar]
  7. Fukuda M., Inomata M., Nishio K., Fukuoka K., Kanzawa F., Arioka H., Ishida T., Fukumoto H., Kurokawa H., Oka M. A topoisomerase II inhibitor, NK109, induces DNA single- and double-strand breaks and apoptosis. Jpn J Cancer Res. 1996 Oct;87(10):1086–1091. doi: 10.1111/j.1349-7006.1996.tb03114.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gottesman M. M., Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem. 1988 Sep 5;263(25):12163–12166. [PubMed] [Google Scholar]
  9. Hong W. S., Saijo N., Sasaki Y., Minato K., Nakano H., Nakagawa K., Fujiwara Y., Nomura K., Twentyman P. R. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer. 1988 Mar 15;41(3):462–467. doi: 10.1002/ijc.2910410325. [DOI] [PubMed] [Google Scholar]
  10. Horichi N., Tapiero H., Sugimoto Y., Bungo M., Nishiyama M., Fourcade A., Lampidis T. J., Kasahara K., Sasaki Y., Takahashi T. 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks. Cancer Res. 1990 Aug 1;50(15):4698–4701. [PubMed] [Google Scholar]
  11. Ishikawa T., Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem. 1993 Sep 25;268(27):20116–20125. [PubMed] [Google Scholar]
  12. Kanzawa F., Hoshi A., Kuretani K., Saneyoshi M., Kawaguchi T. Antitumor activity of 3',5'-diesters of 5-fluoro-2'-deoxyuridine against murine leukemia L1210 cells. Cancer Chemother Pharmacol. 1981;6(1):19–23. doi: 10.1007/BF00253005. [DOI] [PubMed] [Google Scholar]
  13. Kanzawa F., Maeda M., Sasaki T., Hoshi A., Kuretani K. Murine lymphoma L5178Y cells resistant to purine antagonists: differences in cross-resistance to thioguanine-platinum(II) and selenoguanine-platinum(II). J Natl Cancer Inst. 1982 Feb;68(2):287–291. [PubMed] [Google Scholar]
  14. Kanzawa F., Nishio K., Kubota N., Saijo N. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res. 1995 Jul 1;55(13):2806–2813. [PubMed] [Google Scholar]
  15. Kanzawa F., Sugimoto Y., Minato K., Kasahara K., Bungo M., Nakagawa K., Fujiwara Y., Liu L. F., Saijo N. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 1990 Sep 15;50(18):5919–5924. [PubMed] [Google Scholar]
  16. Kaufmann S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 1989 Nov 1;49(21):5870–5878. [PubMed] [Google Scholar]
  17. Kimura I., Ohnoshi T., Hiraki S., Miyamoto H. [Establishment of adriamycin-resistant human small-cell lung cancer cells in culture: analysis of the mechanism of resistance and cross-resistance]. Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 2):830–836. [PubMed] [Google Scholar]
  18. Kondo H., Kanzawa F., Nishio K., Saito S., Saijo N. In vitro and in vivo effects of cisplatin and etoposide in combination on small cell lung cancer cell lines. Jpn J Cancer Res. 1994 Oct;85(10):1050–1056. doi: 10.1111/j.1349-7006.1994.tb02905.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kubota N., Nishio K., Takeda Y., Ohmori T., Funayama Y., Ogasawara H., Ohira T., Kunikane H., Terashima Y., Saijo N. Characterization of an etoposide-resistant human ovarian cancer cell line. Cancer Chemother Pharmacol. 1994;34(3):183–190. doi: 10.1007/BF00685075. [DOI] [PubMed] [Google Scholar]
  20. Larsen A. K., Grondard L., Couprie J., Desoize B., Comoe L., Jardillier J. C., Riou J. F. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol. 1993 Oct 19;46(8):1403–1412. doi: 10.1016/0006-2952(93)90105-6. [DOI] [PubMed] [Google Scholar]
  21. Liu L. F., Miller K. G. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3487–3491. doi: 10.1073/pnas.78.6.3487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Liu L. F., Rowe T. C., Yang L., Tewey K. M., Chen G. L. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem. 1983 Dec 25;258(24):15365–15370. [PubMed] [Google Scholar]
  23. Marini J. C., Miller K. G., Englund P. T. Decatenation of kinetoplast DNA by topoisomerases. J Biol Chem. 1980 Jun 10;255(11):4976–4979. [PubMed] [Google Scholar]
  24. Minato K., Kanzawa F., Nishio K., Nakagawa K., Fujiwara Y., Saijo N. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol. 1990;26(5):313–317. doi: 10.1007/BF02897284. [DOI] [PubMed] [Google Scholar]
  25. Murakami Y., Yasuda H., Miyazawa H., Hanaoka F., Yamada M. Characterization of a temperature-sensitive mutant of mouse FM3A cells defective in DNA replication. Proc Natl Acad Sci U S A. 1985 Mar;82(6):1761–1765. doi: 10.1073/pnas.82.6.1761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Nelson E. M., Tewey K. M., Liu L. F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A. 1984 Mar;81(5):1361–1365. doi: 10.1073/pnas.81.5.1361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Nishio K., Sugimoto Y., Nakagawa K., Niimi S., Fujiwara Y., Bungo M., Kasahara K., Fujiki H., Saijo N. Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin. Br J Cancer. 1990 Sep;62(3):415–419. doi: 10.1038/bjc.1990.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ohmori T., Morikage T., Sugimoto Y., Fujiwara Y., Kasahara K., Nishio K., Ohta S., Sasaki Y., Takahashi T., Saijo N. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Jpn J Cancer Res. 1993 Jan;84(1):83–92. doi: 10.1111/j.1349-7006.1993.tb02788.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ross W., Rowe T., Glisson B., Yalowich J., Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 1984 Dec;44(12 Pt 1):5857–5860. [PubMed] [Google Scholar]
  30. Safa A. R., Glover C. J., Sewell J. L., Meyers M. B., Biedler J. L., Felsted R. L. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem. 1987 Jun 5;262(16):7884–7888. [PubMed] [Google Scholar]
  31. Skovsgaard T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 1978 Jun;38(6):1785–1791. [PubMed] [Google Scholar]
  32. Tewey K. M., Chen G. L., Nelson E. M., Liu L. F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem. 1984 Jul 25;259(14):9182–9187. [PubMed] [Google Scholar]
  33. Tse Y. C., Kirkegaard K., Wang J. C. Covalent bonds between protein and DNA. Formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA. J Biol Chem. 1980 Jun 25;255(12):5560–5565. [PubMed] [Google Scholar]
  34. Tsuruo T., Iida-Saito H., Kawabata H., Oh-hara T., Hamada H., Utakoji T. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res. 1986 Jul;77(7):682–692. [PubMed] [Google Scholar]
  35. Wang J. C. DNA topoisomerases. Annu Rev Biochem. 1985;54:665–697. doi: 10.1146/annurev.bi.54.070185.003313. [DOI] [PubMed] [Google Scholar]
  36. Wang L. K., Johnson R. K., Hecht S. M. Inhibition of topoisomerase I function by nitidine and fagaronine. Chem Res Toxicol. 1993 Nov-Dec;6(6):813–818. doi: 10.1021/tx00036a010. [DOI] [PubMed] [Google Scholar]
  37. Yang C. P., Mellado W., Horwitz S. B. Azidopine photoaffinity labeling of multidrug resistance-associated glycoproteins. Biochem Pharmacol. 1988 Apr 1;37(7):1417–1421. doi: 10.1016/0006-2952(88)90803-9. [DOI] [PubMed] [Google Scholar]
  38. Yoshida M., Feng W., Saijo N., Ikekawa T. Antitumor activity of daphnane-type diterpene gnidimacrin isolated from Stellera chamaejasme L. Int J Cancer. 1996 Apr 10;66(2):268–273. doi: 10.1002/(SICI)1097-0215(19960410)66:2<268::AID-IJC22>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES